Hyosung Chemical Corporation
USPTO PatentsView assignee record - 6 granted patents across 14 technology areas, recorded in grant years 2019–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).
The verdict
According to USPTO PatentsView, Hyosung ranks #40,803 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 14 technology areas.
- #40,803
- of 49,997 US assignees by volume
- 17th percentile
- by Innovation Score (25.4/100)
- 9.0
- avg claims per patent
- +400%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R40803 · Foreign Corporation #40,803 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #40,803/49,997
- PHOTO-FINISH Hydril USA Manufactu…
- CPC-FOCUS C07C · 14 areas
- INNOV-THIN 25.4/100
- CLAIMS-PAR 9.0 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-SURGE +400% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Hydril USA Manufacturing LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Hyosung’s 25.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Hyosung
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Hyosung Chemical · this assignee 25
Hyosung Chemical · this assignee
25 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Hyosung's Innovation Score is 25.4/100 (17th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Hyosung?
Each dot is one of Hyosung’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hyosung’s own 9.0 claims/patent is at or below the 11.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Hyosung's grants concentrate
Hyosung Chemical Corporation is a focused PatentsView assignee: 14 CPC subclasses with 66.7% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2019. By volume, Hyosung sits between HyTest Ltd. and Hyperframe, Inc..
Who files at Hyosung's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Hytest
HyTest Ltd.
6 patents
- Hydril USA Manufa…
Hydril USA Manufacturing LLC
6 patents
- Hydroacoustics
Hydroacoustics Inc.
6 patents
- Hyfra Industrieku…
Hyfra Industriekuhlanlagen GmbH
6 patents
- Hyosung TNC
Hyosung TNC Corporation
6 patents
- Hyperaccel
HyperAccel Co., Ltd.
6 patents
- Hyperbranch Medic…
HyperBranch Medical Technology, Inc.
6 patents
- Hyperframe
Hyperframe, Inc.
6 patents
- Hyosung Chemical ◀
Hyosung Chemical Corporation
6 patents
What this shows Hyosung holds 6 patents at rank #40,795, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Hyosung
By rank, the assignees closest to #40,795 in granted patent volume.
- HyTest Ltd. #40,791 · 6 patents
- Hydril USA Manufacturing LLC #40,792 · 6 patents
- Hydroacoustics Inc. #40,793 · 6 patents
- Hyfra Industriekuhlanlagen GmbH #40,794 · 6 patents
- Hyosung TNC Corporation #40,796 · 6 patents
- HyperAccel Co., Ltd. #40,797 · 6 patents
- HyperBranch Medical Technology, Inc. #40,798 · 6 patents
- Hyperframe, Inc. #40,799 · 6 patents
Leaders in C07C (Acyclic OR Carbocyclic Compounds)
Other assignees with the most granted patents in Hyosung's primary technology class.
Hyosung's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
25 17th percentile higher than 17% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 16.7% |
| 2020 | 2 | 33.3% |
| 2021 | 3 | 50.0% |
Which technologies does Hyosung Chemical Corporation patent most?
Top 14 of 14 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Hyosung Chemical Corporation's patent record in context - here's where to go next.
- Hyosung Chemical Corporation's lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 66.7% of its portfolio - see every assignee active in that class. Explore C07C
- Ranked #40,803 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Hyosung Chemical Corporation against HyTest Ltd., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 25.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.